PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Mayo Clinic researchers find new molecule to target in pancreatic cancer treatment

2013-01-04
(Press-News.org) JACKSONVILLE, Fla. — Researchers at Mayo Clinic in Florida have identified a new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more than 95 percent of pancreatic cancer cases. This fast-growing, often lethal cancer is resistant to conventional chemotherapy. The findings are published in the Jan. 3 online issue of PLOS ONE.

The researchers decoded a molecular pathway that is switched "on" at all times, promoting accelerated growth of pancreatic tumors, and that discovery revealed ways to disable the pathway. They say one strategy could involve the use of the drug bortezomib, which is already approved for several human blood cancers.

"Targeting this pathway to decrease the proliferation of cancer cells may represent a new strategy for pancreatic cancer therapy," says the study's senior investigator, Peter Storz, Ph.D., a biochemist and molecular biologist at Mayo Clinic.

One feature of pancreatic cancer is increased activity of the transcription factor NF-kB, which turns on expression of genes that keep the cells proliferating and protect them from death. There are two pathways, known as the classical and alternative, by which NF-kB can be activated, and the researchers looked at the alternative pathway — one in which NF-kB is activated differently, and which switches on other genes, compared to the classical signaling pathway. Both the classical and alternative pathways are active in pancreatic cancer.

The research team discovered that increased activity of the alternative NF-kB pathway results from suppression of TNF receptor-associated factor 2, or TRAF2. Loss of TRAF2 promotes fast growth of pancreatic tumors and correlates with increased aggressiveness, Dr. Storz says.

They tested this discovery in 55 human samples of pancreatic cancer, and found that in 69 percent, TRAF2 wasn't functioning properly and there were higher levels of other molecules participating in the alternative pathway. A cocktail of drugs that includes chemotherapy, bortezomib and other inhibitors of molecules activated along the pathway may help pancreatic cancer patients, Dr. Storz says.

"Of course, this hypothesis requires extensive clinical testing, but our findings offer a new direction to investigate in improving treatment of pancreatic cancer," he says.

###

The research team includes cancer biologists Heike Döppler and Geou-Yarh Liou, Ph.D. from Mayo Clinic in Florida. The study was funded by grants from the American Association for Cancer Research and the National Institutes of Health (grant numbers CA135102, CA140182 and P50CA102701).

About Mayo Clinic Cancer Center

As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.

About Mayo Clinic

Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.com and www.mayoclinic.org/news.

Journalists can become a member of the Mayo Clinic News Network for the latest health, science and research news and access to video, audio, text and graphic elements that can be downloaded or embedded.

END



ELSE PRESS RELEASES FROM THIS DATE:

Editing the genome with high precision

2013-01-04
CAMBRIDGE, MA -- Researchers at MIT, the Broad Institute and Rockefeller University have developed a new technique for precisely altering the genomes of living cells by adding or deleting genes. The researchers say the technology could offer an easy-to-use, less-expensive way to engineer organisms that produce biofuels; to design animal models to study human disease; and to develop new therapies, among other potential applications. To create their new genome-editing technique, the researchers modified a set of bacterial proteins that normally defend against viral invaders. ...

An embryo that is neither male nor female

2013-01-04
So, is it a girl or a boy? This is the first question parents ask at the birth of an infant. Though the answer is obvious, the mechanism of sex determination is much less so. Researchers at the University of Geneva (UNIGE) attempt to shed light on this complex process by identifying the crucial role played by insulin and IGF1 and IGF2 growth factors, a family of hormones known for its role in metabolism and growth. In the absence of these factors at the time of sex determination, embryos do not differentiate into either male or female and have no adrenal glands. The results ...

Turning smartphones into secure and versatile keys

Turning smartphones into secure and versatile keys
2013-01-04
Smartphones and tablets have become an integral part of our daily lives. The capabilities of these handily sized mini-computers seem almost boundless as we phone friends, shoot holiday snaps, lose ourselves in a new music download or access the internet to obtain the boarding card for our next fl ight in comfort. Does it not seem logical, then, that we should make use of these constant companions as the key to our cars, front doors or lockers as well? A few such solutions are already available, but what's still missing is widespread market acceptance. At this year's CeBIT ...

Scientists discover how deadly skin cancer spreads into other parts of the body

Scientists discover how deadly skin cancer spreads into other parts of the body
2013-01-04
After recently announcing success in eliminating melanoma metastasis in laboratory experiments, scientists at Virginia Commonwealth University Massey Cancer Center have made another important discovery in understanding the process by which the gene mda-9/syntenin contributes to metastasis in melanoma (the spread of skin cancer) and possibly a variety of other cancers. Published in the journal Cancer Research, the study demonstrated that mda-9/syntenin is a key regulator of angiogenesis, the process responsible for the formation of new blood vessels in tumors. Mda-9/syntenin ...

Liquid jets and bouncing balls combine for surprising results

2013-01-04
A new study published in the American Institute of Physics' (AIP) journal Physics of Fluids reveals that the normal rebounding of a ball changes when it is partially filled with a liquid. Unlike an empty sphere or a solid rubber ball, which both rebound in a classical and well-understood fashion, a fluid-filled ball has its second bounce remarkably cut short. A team of researchers from Brigham Young University in Provo, Utah, uncovered this phenomenon when they investigated what would happen if a sphere were partially filled with a liquid and how that would affect the way ...

Power spintronics: Producing AC voltages by manipulating magnetic fields

2013-01-04
Scientists are putting a new spin on their approach to generating electrical current by harnessing a recently identified electromotive force known as spinmotive force, which is related to the field of spintronics that addresses such challenges as improving data storage in computers. Now, a novel application of spintronics is the highly efficient and direct conversion of magnetic energy to electric voltage by using magnetic nanostructures and manipulating the dynamics of magnetization. According to a report published in the American Institute of Physics' (AIP) journal Applied ...

UC Davis study links low wages with hypertension, especially for women and younger workers

2013-01-04
(SACRAMENTO, Calif.) — Workers earning the lowest wages have a higher risk of hypertension than workers with the highest wages, according to new research from UC Davis. The correlation between wages and hypertension was especially strong among women and persons between the ages of 25 to 44. "We were surprised that low wages were such a strong risk factor for two populations not typically associated with hypertension, which is more often linked with being older and male," said J. Paul Leigh, senior author of the study and professor of public health sciences at UC Davis. ...

Sorting stem cells

2013-01-04
When an embryonic stem cell is in the first stage of its development it has the potential to grow into any type of cell in the body, a state scientists call undifferentiated. A team of researchers from Scotland has now demonstrated a way to easily distinguish undifferentiated embryonic stem cells from later-stage stem cells whose fate is sealed. The results are published in the American Institute of Physics' (AIP) journal Biomicrofluidics. The researchers used an electric field to pull stem cells through a fluid in a process called dielectrophoresis. They varied the frequency ...

New understanding of nerve damage caused by spinal cord injury could improve treatment design

New understanding of nerve damage caused by spinal cord injury could improve treatment design
2013-01-04
New Rochelle, NY, January 3, 2013—More than half of traumatic spinal cord injuries (SCI) in humans are cervical lesions, resulting in chronic loss of limb function. A better understanding of the link between the neurologic damage caused by SCI, spontaneous motor function recovery, and long-term motor deficits would lead to better therapeutic approaches, as discussed in an article in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Neurotrauma website at http://www.liebertpub.com/neu. About ...

Carbon in Vesta's craters

Carbon in Vestas craters
2013-01-04
The protoplanet Vesta has been witness to an eventful past: images taken by the framing camera onboard NASA's space probe Dawn show two enormous craters in the southern hemisphere. The images were obtained during Dawn's year-long visit to Vesta that ended in September 2012. These huge impacts not only altered Vesta's shape, but also its surface composition. Scientists under the lead of the Max Planck Institute for Solar System Research in Katlenburg-Lindau in Germany have shown that impacting small asteroids delivered dark, carbonaceous material to the protoplanet. In the ...

LAST 30 PRESS RELEASES:

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy

NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC

Training to improve memory

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

Black youth, especially Black girls, use mental health services less than their White peers

Canada must protect youth from sports betting advertising

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Higher blood pressure in childhood linked to earlier death from heart disease in adulthood

AI helped older adults report accurate blood pressure readings at home

High blood pressure in childhood and premature cardiovascular disease mortality

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital

New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment

New insights into energy metabolism and immune dynamics could transform head and neck cancer treatment

Pennington Biomedical’s Dr. Steven Heymsfield named LSU Boyd Professor – LSU’s highest faculty honor

Study prompts new theory of human-machine communication

[Press-News.org] Mayo Clinic researchers find new molecule to target in pancreatic cancer treatment